Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 40 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.
Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.
Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
- Dene Peters
- Publishing model
- Hybrid. Open Choice – What is this?
- Impact factor: 4.993 (2018)
- Five year impact factor: 4.647 (2018)
- Submission to first decision: 36 days
- Acceptance to publication: 14 days
- Downloads: 408,043 (2018)